The Guardant Health team believes that blood-based testing is the key to transforming cancer care by providing patients and their providers actionable insights to make informed treatment decisions. The driving force of their work is our commitment to putting patients first, and they continue to strive to help patients across every stage of cancer live longer, healthier lives.
Guardant Health + Pear
The Pear team began partnering with Guardant Health’s founders, Helmy and AmirAli, in 2013.
They knew precision oncology had the power to make a profound impact on the fight against cancer. They had a vision and a mission, but what they needed was the support and backing – that’s where Pear came in.
Pear provided Helmy and AmirAli with the network and funding to support growth as they spent time in the lab developing the next generation of blood-based tests. They’ve since launched 15 innovative products to improve cancer outcomes at every stage of the disease.
Guardant took a risk trying to bring these futuristic blood tests into the clinical setting. Pear understood the value of their technology and partnered with them to ensure we succeeded.
When you get into a field of potential big needs but with a technology gap, there will be a lot of naysayers. Pear believed in Guardant’s mission and partnered with them to make it a reality for patients and providers.
Biotech startups are more capital intensive, generating revenue takes many years, and requires domain expertise. We understood this and supported Helmy and AmirAli as they grew their technology and team.
We’re proud to have supported them in every round of financing through their IPO in 2018.
Sector
Biotech
First Investment
Seed
Current Stage
IPO
Headquarters
Palo Alto, CA
Biotech startups are more capital intensive, generating revenue takes many years, and requires domain expertise. Pear understood this and supported us as we grew our technology and our team, treating us like family each step of the way.
AmirAli Talasaz, PhD Co-CEO, Guardant Health